References
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–54.
Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 190–209.
Zarbo A, Belum VR, Sibaud V, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol 2017; 176: 1649–52.
Bertolini M, Zilio F, Rossi A, et al. Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata. PLoS One 2014; 9: e94260.
Wang X, Marr AK, Breitkopf T, et al. Hair follicle mesenchyme-associated PD-L1 regulates T-cell activation induced apoptosis: a potential mechanism of immune privilege. J Invest Dermatol 2014; 134: 736–45.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure. Financial support: none. Conflicts of interest: none.
About this article
Cite this article
Komatsu-Fujii, T., Otsuka, A., Ishida, Y. et al. Diffuse hair loss following anti-programmed cell death-1 antibody treatment: a case report with immunohistochemical analysis. Eur J Dermatol 29, 326–327 (2019). https://doi.org/10.1684/ejd.2019.3547
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2019.3547